Business
Notification of first patent grant
Notification of first patent grant.
About this update from Skinbiotherapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 0661Y SkinBioTherapeutics PLC 30 November 2017 \n\nSkinBioTherapeutics plc\n \nNotification of first patent grant\n \nManchester, UK - 1 December 2017 - SkinBioTherapeutics plc (AIM: SBTX, the \"Company\"), a life science company focused on skin health, announces the granting of the first patent for its SkinBiotix® technology in Australia. \nThe patent granted covers the use of specific probiotic bacteria and lysates in the treatment of skin in health and disease. This marks the Company's first patent to progress to grant from within its portfolio of patents pending estate. The patent, numbered 2013246701 and entitled 'Probiotic bacteria', runs until 15 March 2033.\nThe patent is in active prosecution in other locations worldwide including Europe, USA and China. \nDr Catherine O'Neill, CEO of SkinBioTherapeutics, commented:\n\"The Australian skincare market is a key global market. The progression and successful grant of the first national patent to emerge from the Company's Skinbiotix® patent family underpins the commercial potential worldwide. \n \n\"This is a step forward in preparing for human trials, which are scheduled for 2018.\"\n \nThis announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.\n \n-Ends-\n \nFor more information, please contact: \n \n\n\n\n\nSkinBioTherapeutics plc\nDr. Cath O'Neill, CEO\nDoug Quinn, CFO \n \n\n\nTel: +44 (0) 161 468 2760\n\n\n\n\nCairn Financial Advisers LLP\nTony Rawlinson / Emma Earl / Richard Nash\n \n\n\nTel: +44 (0) 20 7213 0880\n\n\n\n\nTurner Pope Investments\nBen Turner / James Pope\n \n\n\nTel: +44 (0) 20 3621 4120\n \n\n\n\n\nInstinctif Partners\nMelanie Toyne-Sewell / Deborah Bell \n\n\nTel: +44 (0) 20 7457 2020\[email protected] \n\n\n\n\n \nNotes to Editors\nAbout SkinBioTherapeutics plc\nSkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O'Neill and Professor Andrew McBain. \nSkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix® platform can improve the bar...